SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

SunTrust Robinson Humphrey Downgrades Allogene Therapeutics to Hold, Raises Price Target of $32

SunTrust Robinson Humphrey analyst Asthika Goonewardene downgrades Allogene Therapeutics (NASDAQ:ALLO) from Buy to Hold and raises the price target from $29 to $32.

Benzinga · 05/14/2020 11:20

SunTrust Robinson Humphrey analyst Asthika Goonewardene downgrades Allogene Therapeutics (NASDAQ:ALLO) from Buy to Hold and raises the price target from $29 to $32.